PHARMExcel to support trial delivery of world-first Covid-19 vaccine booster study.
PHARMExcel is delighted to be announced as the UK Contract Research Organisation (CRO) supporting University Hospital Southampton in the delivery of a world-first Covid-19 vaccine booster study. The Cov-Boost study, backed by £19.3 million of government funding through the Vaccines Taskforce, will be run at University Hospital Southampton, University Hospitals Dorset and the Portsmouth Research…
PHARMExcel instrumental in supporting the re-opening of Biotherapy Services DFU trial
Biotherapy Services are very pleased to announce our RAPID-1 (Diabetic Foot Ulcer) trial has enrolled and dosed its first patient following suspension of the trial due to the Covid-19 pandemic restrictions. This could only have been made possible with the collaborative approach from the PHARMExcel team, who took over the trial management in early 2020….
PHARMExcel selected as INmuneBio’s UK CRO to lead on their Phase I clinical trial of INKmune in MDS patients
PHARMExcel are delighted to have be selected as INmuneBio’s U.K. CRO to lead on their Phase I clinical trial of INKmune, a novel therapy to prime the patient’s own Natural Killer (NK) cells to attack their cancer, in patients with high-risk Myelodysplastic Syndrome (MDS) (EUDRACT 2019-004820-40). This is a single center, Phase I trial and will…
Effective CRO Project Management and Fast Track Study Set-Up for an Investigator Initiated COVID-19 study
BACKGROUND PHARMExcel was selected to manage a UK, Phase II, combined Investigational Medicinal Product (IMP)/Medical Device study for COVID-19 patients hospitalised in ICU. We were asked to provide Project Management (PM), Monitoring and Safety oversight for the study, from protocol development to close-out. The study involved two sites and numerous teams responsible for key elements…